TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07416123: First-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors

Sponsor: Genmab · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 103 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$6,785,856

Rescue Site Savings

+$4,492,488

Unlock Full NCT07416123 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07416123 Rescue Dossier →